Skip to main content

About the Lab

The Yong Li Laboratory integrates artificial intelligence, computational biology, and experimental validation to advance the fundamental understanding of cancer and develop innovative molecular and cellular therapeutics. Our research focuses on targeting mutant p53 proteins and other clinically relevant tumor antigens, with the goal of translating biological discoveries into transformative cancer therapies.

Cancer Prevention and Interception

Dr. Yong Li directs a U54 Cancer Prevention and Interception Center, funded by the National Cancer Institute's Division of Cancer Prevention. The Center is dedicated to preventing the progression of monoclonal gammopathy of undetermined significance (MGUS), a premalignant condition characterized by the presence of abnormal monoclonal immunoglobulin (M protein) in the blood. Through multidisciplinary collaboration, the Center develops and evaluates immunologically and chemically targeted interventions aimed at preventing or intercepting malignant transformation in patients with MGUS and related smoldering disorders.

Targeting Hotspot p53 Mutants

Rather than attempting to repair mutant p53, we seek to directly target mutant p53 proteins in their existing conformations using highly specific monoclonal antibodies. Our vision is to develop antibody-based therapeutics that selectively recognize cancer-associated p53 mutants while sparing wild-type p53, thereby enabling precision treatment for patients whose tumors harbor these mutations.

Artificial Intelligence in Antibody Discovery

The Li Laboratory combines AI-driven design with automated high-throughput screening and experimental validation to discover next-generation antibodies against both intracellular and cell-surface tumor antigens. 

Leader

Dr. Yong Li serves as the Director of the Center for Molecular Oncology and Cellular Therapeutics at the Children's Mercy Research Institute.

Dr. Li’s research combines artificial intelligence with experimental validation to elucidate the fundamental biology of cancer and to develop molecular and cellular therapeutics targeting p53 mutants and other tumor antigens. At Children’s Mercy, Dr. Li is committed to translating scientific discoveries into innovative immunotherapy treatments for pediatric patients and beyond and strengthening collaborations with the University of Kansas Cancer Center.